Mei-Chen Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mei-Chen Yang has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Chou-Chin Lan
Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan
21 shared publications - Yao-Kuang Wu
Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan
15 shared publications - I-Shiang Tzeng
Department of Medical Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231016, Taiwan
12 shared publications - Wen-Lin Su
Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan
11 shared publications Yao-Kuang Wu
11 shared publicationsChou-Chin Lan
10 shared publications
Latest Publications
- 17 November 2026
- Published by Elsevier in European Journal of Pharmacology
NKCC1 in Sepsis-Related Acute Lung Injury: Emerging Links to Macrophage–Neutrophil Crosstalk
- 17 November 2026
- Published by Elsevier in European Journal of Pharmacology
NKCC1 in Sepsis-Related Acute Lung Injury: Emerging Links to Macrophage–Neutrophil Crosstalk
- Open Access
- 1 November 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Outcomes of AECOPD Under a Multidisciplinary Team Model: A 7-Year Analysis Across the COVID-19 Era in Taiwan
Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a leading cause of hospitalisation and mortality. Although multidisciplinary team (MDT) care models are increasingly used in disease management, long-term real-world data, particularly during the coronavirus disease 2019 (COVID-19) pandemic, remain limited. Methods: We conducted a retrospective analysis of patients hospitalised for AECOPD between 2018 and 2024. A LINE-based MDT model was implemented in 2019. Outcomes included pharmacological and nonpharmacological intervention rates, psychological well-being, health-related quality of life (HRQL), hospital length of stay (LOS), readmissions, and 1-year survival. Results: Among 568 patients, the use of several guideline-based treatments differed significantly across study years, including long-acting muscarinic antagonists (64% in 2018 to 93% in 2024), long-acting beta-agonists (74% to 100%), systemic corticosteroids (79% to 96%), and inhaled corticosteroids (59% to 86%) (all p< 0.001). Pulmonary rehabilitation differed significantly across years (p< 0.001), increasing from 51.9% in 2018 to 98.6% in 2024 despite a temporary decline in 2022. Smoking cessation success also differed across years (p=0.006). The 14-day readmission rate differed significantly across years (p=0.043), ranging from a peak of 17.3% in 2020 to 2.9% in 2024. No significant differences across years were observed in LOS or 1-year survival. Psychological distress and CAT scores also differed across study years. Conclusion: The LINE-based MDT model was associated with higher rates of several care-process measures, particularly pulmonary rehabilitation. However, adjusted comparisons between 2024 and 2018 showed no significant differences in major hospital outcomes. These observational findings suggest a potential role for digitally coordinated MDT care in supporting multidisciplinary AECOPD care, although causal effects cannot be established. Trial Registration: Not applicable.
- 1 November 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-13
Open AccessOutcomes of AECOPD Under a Multidisciplinary Team Model: A 7-Year Analysis Across the COVID-19 Era in Taiwan
Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a leading cause of hospitalisation and mortality. Although multidisciplinary team (MDT) care models are increasingly used in disease management, long-term real-world data, particularly during the coronavirus disease 2019 (COVID-19) pandemic, remain limited. Methods: We conducted a retrospective analysis of patients hospitalised for AECOPD between 2018 and 2024. A LINE-based MDT model was implemented in 2019. Outcomes included pharmacological and nonpharmacological intervention rates, psychological well-being, health-related quality of life (HRQL), hospital length of stay (LOS), readmissions, and 1-year survival. Results: Among 568 patients, the use of several guideline-based treatments differed significantly across study years, including long-acting muscarinic antagonists (64% in 2018 to 93% in 2024), long-acting beta-agonists (74% to 100%), systemic corticosteroids (79% to 96%), and inhaled corticosteroids (59% to 86%) (all p< 0.001). Pulmonary rehabilitation differed significantly across years (p< 0.001), increasing from 51.9% in 2018 to 98.6% in 2024 despite a temporary decline in 2022. Smoking cessation success also differed across years (p=0.006). The 14-day readmission rate differed significantly across years (p=0.043), ranging from a peak of 17.3% in 2020 to 2.9% in 2024. No significant differences across years were observed in LOS or 1-year survival. Psychological distress and CAT scores also differed across study years. Conclusion: The LINE-based MDT model was associated with higher rates of several care-process measures, particularly pulmonary rehabilitation. However, adjusted comparisons between 2024 and 2018 showed no significant differences in major hospital outcomes. These observational findings suggest a potential role for digitally coordinated MDT care in supporting multidisciplinary AECOPD care, although causal effects cannot be established. Trial Registration: Not applicable.
- Open Access
- 25 July 2026
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 55
Comparisons of Continuous Positive Airway Pressures Determined by Conventional Manual Titration in a Sleep Center, During Sleep Endoscopy, and Auto-Titration at Home
Importance: Drug-induced sleep endoscopy (DISE) could be valuable to determine an appropriate therapeutic pressure for obstructive sleep apnea (OSA). Objective: The continuous positive airway pressure (CPAP) determined by DISE was regarded as equal to the conventional titrating pressure. There is no study comparing the DISE-titrating pressure and the home-based automatic CPAP (APAP) titrating pressure. This study compared the DISE-titrating pressure, conventional titrating pressure, and home-based APAP titrating pressure. Design: Retrospective comparative cohort study. Setting: This study was conducted in a single medical center in Taiwan. Participants: A total of 59 participants with OSA who had 3 titrating pressures determined by DISE, conventional titration and home-based APAP titration were analyzed. Interventions or Exposures: Therapeutic CPAP pressure was determined by 3 methods: DISE, conventional titration, and home-based APAP titration. Main Outcome Measures: Home-based APAP titrating pressure was determined as 90% to 95% of APAP used at home for 2 weeks. The DISE-titrating pressure was determined manually based on direct visualization of upper airway patency during DISE examination. The conventional titrating pressure was determined manually under polysomnography (PSG) guidance in a sleep center. The correlation and difference between these 3 pressures were analyzed. Results: The home-based APAP titrating pressure, conventional titrating pressure, and DISE-titrating pressure were 8.8, 8.1, and 8.2 cmH 2 O, respectively. Good reliability was observed in pairs between all 3 pressures. The DISE-titrating pressure and the conventional titrating pressure were lower than the home-based APAP titrating pressure. There was no difference between the DISE-titrating pressure and the conventional titrating pressure. Conclusions: DISE could help provide a therapeutic CPAP pressure similar to the conventional titrating pressure in sleep center and APAP titrating pressure at home. Relevance: DISE could be a valuable alternative titrating method, especially in countries where PSG is expensive, time-consuming and difficult to access, and could facilitate earlier and more effective management of patients with OSA.
- 25 July 2026
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 55
Open AccessComparisons of Continuous Positive Airway Pressures Determined by Conventional Manual Titration in a Sleep Center, During Sleep Endoscopy, and Auto-Titration at Home
Importance: Drug-induced sleep endoscopy (DISE) could be valuable to determine an appropriate therapeutic pressure for obstructive sleep apnea (OSA). Objective: The continuous positive airway pressure (CPAP) determined by DISE was regarded as equal to the conventional titrating pressure. There is no study comparing the DISE-titrating pressure and the home-based automatic CPAP (APAP) titrating pressure. This study compared the DISE-titrating pressure, conventional titrating pressure, and home-based APAP titrating pressure. Design: Retrospective comparative cohort study. Setting: This study was conducted in a single medical center in Taiwan. Participants: A total of 59 participants with OSA who had 3 titrating pressures determined by DISE, conventional titration and home-based APAP titration were analyzed. Interventions or Exposures: Therapeutic CPAP pressure was determined by 3 methods: DISE, conventional titration, and home-based APAP titration. Main Outcome Measures: Home-based APAP titrating pressure was determined as 90% to 95% of APAP used at home for 2 weeks. The DISE-titrating pressure was determined manually based on direct visualization of upper airway patency during DISE examination. The conventional titrating pressure was determined manually under polysomnography (PSG) guidance in a sleep center. The correlation and difference between these 3 pressures were analyzed. Results: The home-based APAP titrating pressure, conventional titrating pressure, and DISE-titrating pressure were 8.8, 8.1, and 8.2 cmH 2 O, respectively. Good reliability was observed in pairs between all 3 pressures. The DISE-titrating pressure and the conventional titrating pressure were lower than the home-based APAP titrating pressure. There was no difference between the DISE-titrating pressure and the conventional titrating pressure. Conclusions: DISE could help provide a therapeutic CPAP pressure similar to the conventional titrating pressure in sleep center and APAP titrating pressure at home. Relevance: DISE could be a valuable alternative titrating method, especially in countries where PSG is expensive, time-consuming and difficult to access, and could facilitate earlier and more effective management of patients with OSA.
- Open Access
- 1 July 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-10
Carbon Emissions and Treatment Efficiency in Chronic Obstructive Pulmonary Disease: The Impact of Inhaled Bronchodilators and Corticosteroids
- 1 July 2026
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 21, 1-10
Open AccessCarbon Emissions and Treatment Efficiency in Chronic Obstructive Pulmonary Disease: The Impact of Inhaled Bronchodilators and Corticosteroids
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-12
Bronchial Hyperreactivity in the COVID-19 Era: The Impact of SARS-CoV-2 Infection and COVID-19 Vaccination in Patients with Respiratory Symptoms
Persistent respiratory symptoms are commonly reported following coronavirus disease 2019 (COVID-19). Although COVID-19 vaccines are effective, concerns remain regarding their potential impact on airway hypersensitivity. The relationship between SARS-CoV-2 infection, vaccination, and bronchial hyperresponsiveness remains unclear. This retrospective study included adults aged ≥18 years who underwent methacholine provocation testing. Participants were categorized into four groups according to their history of SARS-CoV-2 infection and COVID-19 vaccination: no infection/no vaccination (NI-NV), vaccination/no infection (V-NI), no vaccination/infection (NV–I), and vaccination/infection (V–I). Airway hypersensitivity was defined as a ≥20% reduction in forced expiratory volume in one second (FEV1) following methacholine challenge. Multivariable logistic regression analysis was performed to evaluate independent associations. A total of 340 participants were included (NI-NV: n=36; V-NI: n=163; NV-I: n=25; V-I: n=116). No significant differences were observed in methacholine positivity, pulmonary function parameters, or PC20 values across groups (all p>0.05). In multivariable analysis, neither prior infection (adjusted OR 0.99, 95% CI 0.63–1.55) nor vaccination (adjusted OR 1.06, 95% CI 0.60–1.88) was independently associated with bronchial hyperresponsiveness. Smoking was significantly associated with methacholine positivity (adjusted OR 3.33, 95% CI 1.43–7.77). Symptom severity differed among groups, with higher cough and sputum scores in the NI-NV group and greater dyspnea severity in the NV-I group. Neither prior SARS-CoV-2 infection nor COVID-19 vaccination was associated with increased airway hypersensitivity after adjustment for confounders. Despite similar objective airway responsiveness, symptom severity varied across groups, suggesting a dissociation between subjective respiratory symptoms and measurable bronchial hyperresponsiveness.
- 1 April 2026
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 19, 1-12
Open AccessBronchial Hyperreactivity in the COVID-19 Era: The Impact of SARS-CoV-2 Infection and COVID-19 Vaccination in Patients with Respiratory Symptoms
Persistent respiratory symptoms are commonly reported following coronavirus disease 2019 (COVID-19). Although COVID-19 vaccines are effective, concerns remain regarding their potential impact on airway hypersensitivity. The relationship between SARS-CoV-2 infection, vaccination, and bronchial hyperresponsiveness remains unclear. This retrospective study included adults aged ≥18 years who underwent methacholine provocation testing. Participants were categorized into four groups according to their history of SARS-CoV-2 infection and COVID-19 vaccination: no infection/no vaccination (NI-NV), vaccination/no infection (V-NI), no vaccination/infection (NV–I), and vaccination/infection (V–I). Airway hypersensitivity was defined as a ≥20% reduction in forced expiratory volume in one second (FEV1) following methacholine challenge. Multivariable logistic regression analysis was performed to evaluate independent associations. A total of 340 participants were included (NI-NV: n=36; V-NI: n=163; NV-I: n=25; V-I: n=116). No significant differences were observed in methacholine positivity, pulmonary function parameters, or PC20 values across groups (all p>0.05). In multivariable analysis, neither prior infection (adjusted OR 0.99, 95% CI 0.63–1.55) nor vaccination (adjusted OR 1.06, 95% CI 0.60–1.88) was independently associated with bronchial hyperresponsiveness. Smoking was significantly associated with methacholine positivity (adjusted OR 3.33, 95% CI 1.43–7.77). Symptom severity differed among groups, with higher cough and sputum scores in the NI-NV group and greater dyspnea severity in the NV-I group. Neither prior SARS-CoV-2 infection nor COVID-19 vaccination was associated with increased airway hypersensitivity after adjustment for confounders. Despite similar objective airway responsiveness, symptom severity varied across groups, suggesting a dissociation between subjective respiratory symptoms and measurable bronchial hyperresponsiveness.
- Open Access
- 13 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3077
Impact of Positive Airway Pressure and Mask Leakage on Dry Eye and Glaucoma Risk in Obstructive Sleep Apnea: A Cross-Sectional Analysis
Purpose: This study investigates the association between obstructive sleep apnea (OSA), dry eye disease (DED), and glaucoma, focusing on the impact of positive airway pressure (PAP) usage and air leakage. Methods: This retrospective cross-sectional study included 57 adults with polysomnography-confirmed OSA between 2010 and 2023. Participants were grouped into PAP users (PAP+, n = 40) and non-users (PAP−, n = 17). Ocular assessments included tear film break-up time, Schirmer’s test, Oxford staining, meibomian gland evaluation, intraocular pressure, cup-to-disc (C/D) ratio, and retinal nerve fiber layer thickness. PAP device data (usage duration and air leak rate) and OSA severity metrics were recorded. Group comparisons used chi-square and Student’s t-test, and regression analyses identified associations between PAP leakage and ocular parameters. Results: Among the 57 OSA patients, PAP users showed a trend toward a higher risk of glaucoma (OR = 0.83) and DED (OR = 0.69) compared to non-users, but neither trend was statistically significant. PAP users had significantly more severe OSA, including longer N1 sleep stage (p = 0.0005), higher apnea-hypopnea index (AHI, p = 0.0001), and poorer oxygenation. PAP leakage: 95% (mean = 25.84 L/min) exceeded the 24 L/min threshold specified in ResMed’s clinical guidelines, suggesting suboptimal therapy. Higher PAP leak was significantly associated with a lower Schirmer’s test value (p = 0.031) and a higher C/D ratio (p = 0.040) on regression analysis. However, no significant differences were found in ophthalmic parameters between PAP+ and PAP− groups. Conclusions: Suboptimal PAP therapy as mask leakage or nocturnal hemodynamic changes may worsen evaporative dry eye and affect intraocular pressure. Our findings highlight the association between PAP mask leakage and reduced tear production, and suggest that OSA-related optic nerve stress may persist unless both hypoxia and nocturnal IOP fluctuations are properly managed. However, due to the relatively small sample size and retrospective cross-sectional design, future prospective studies with larger cohorts are needed to confirm these associations.
- 13 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 3077
Open AccessImpact of Positive Airway Pressure and Mask Leakage on Dry Eye and Glaucoma Risk in Obstructive Sleep Apnea: A Cross-Sectional Analysis
Purpose: This study investigates the association between obstructive sleep apnea (OSA), dry eye disease (DED), and glaucoma, focusing on the impact of positive airway pressure (PAP) usage and air leakage. Methods: This retrospective cross-sectional study included 57 adults with polysomnography-confirmed OSA between 2010 and 2023. Participants were grouped into PAP users (PAP+, n = 40) and non-users (PAP−, n = 17). Ocular assessments included tear film break-up time, Schirmer’s test, Oxford staining, meibomian gland evaluation, intraocular pressure, cup-to-disc (C/D) ratio, and retinal nerve fiber layer thickness. PAP device data (usage duration and air leak rate) and OSA severity metrics were recorded. Group comparisons used chi-square and Student’s t-test, and regression analyses identified associations between PAP leakage and ocular parameters. Results: Among the 57 OSA patients, PAP users showed a trend toward a higher risk of glaucoma (OR = 0.83) and DED (OR = 0.69) compared to non-users, but neither trend was statistically significant. PAP users had significantly more severe OSA, including longer N1 sleep stage (p = 0.0005), higher apnea-hypopnea index (AHI, p = 0.0001), and poorer oxygenation. PAP leakage: 95% (mean = 25.84 L/min) exceeded the 24 L/min threshold specified in ResMed’s clinical guidelines, suggesting suboptimal therapy. Higher PAP leak was significantly associated with a lower Schirmer’s test value (p = 0.031) and a higher C/D ratio (p = 0.040) on regression analysis. However, no significant differences were found in ophthalmic parameters between PAP+ and PAP− groups. Conclusions: Suboptimal PAP therapy as mask leakage or nocturnal hemodynamic changes may worsen evaporative dry eye and affect intraocular pressure. Our findings highlight the association between PAP mask leakage and reduced tear production, and suggest that OSA-related optic nerve stress may persist unless both hypoxia and nocturnal IOP fluctuations are properly managed. However, due to the relatively small sample size and retrospective cross-sectional design, future prospective studies with larger cohorts are needed to confirm these associations.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 941-954
Comparative Analysis of ICS Combined with LABA versus Addition of Omalizumab on Transcriptomic Expression Profiles in Patients with Allergic Asthma
Introduction: Asthma causes airway inflammation, leading to symptoms that impair patients’ quality of life, making it a significant global public health issue. Inhaled corticosteroids (ICS) with long-acting beta-agonists therapy (LABA) is commonly used to manage moderate to severe asthma. For patients unresponsive to ICS with LABA, omalizumab may be added to improve asthma control. Understanding transcriptomic expressions is crucial as it provides insights into the molecular mechanisms underlying treatment. However, the impact of omalizumab on transcriptomic expressions remains unclear. Therefore, this study aims to investigate the transcriptomic expression profiles and clinical outcomes between patients receiving ICS with LABA therapy and those adding omalizumab. Materials and Methods: This is a prospective, real-world study that enrolled 26 participants, divided into three groups: Group 1, ICS with LABA (n=10); Group 2, ICS with LABA plus omalizumab (n=12); and Group 3, healthy controls (n=4). Assessments included transcriptomic expression profiles, and bioinformatics analysis, IgE, airborne allergen test, pulmonary function test, blood tests, and asthma control test (ACT). Results: ACT scores were significantly higher in Group 1 and 2 compared to Group 3. IgE levels, dust mite sensitivity, and dynamic pulmonary function changes after bronchodilator administration were notably higher in Group 2. In these patients, down-regulated genes included those related to immune response, NOD-like receptor signaling, RIG-I signaling, IL-17 signaling, and antioxidant activity. Conversely, up-regulated genes were found in the cGMP-PKG signaling pathway, cardiomyopathy-related pathways, and voltage-gated calcium channel activity. Conclusion: Patients receiving ICS with LABA plus omalizumab still exhibited more dynamic airway changes and higher IgE levels. Downregulation of immune and inflammatory pathways suggests its potential as an add-on treatment for severe asthma. However, upregulated genes were observed in the cGMP-PKG signaling pathway, cardiomyopathy-related pathways, and voltage-gated calcium channel activity.
- 1 June 2025
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 18, 941-954
Open AccessComparative Analysis of ICS Combined with LABA versus Addition of Omalizumab on Transcriptomic Expression Profiles in Patients with Allergic Asthma
Introduction: Asthma causes airway inflammation, leading to symptoms that impair patients’ quality of life, making it a significant global public health issue. Inhaled corticosteroids (ICS) with long-acting beta-agonists therapy (LABA) is commonly used to manage moderate to severe asthma. For patients unresponsive to ICS with LABA, omalizumab may be added to improve asthma control. Understanding transcriptomic expressions is crucial as it provides insights into the molecular mechanisms underlying treatment. However, the impact of omalizumab on transcriptomic expressions remains unclear. Therefore, this study aims to investigate the transcriptomic expression profiles and clinical outcomes between patients receiving ICS with LABA therapy and those adding omalizumab. Materials and Methods: This is a prospective, real-world study that enrolled 26 participants, divided into three groups: Group 1, ICS with LABA (n=10); Group 2, ICS with LABA plus omalizumab (n=12); and Group 3, healthy controls (n=4). Assessments included transcriptomic expression profiles, and bioinformatics analysis, IgE, airborne allergen test, pulmonary function test, blood tests, and asthma control test (ACT). Results: ACT scores were significantly higher in Group 1 and 2 compared to Group 3. IgE levels, dust mite sensitivity, and dynamic pulmonary function changes after bronchodilator administration were notably higher in Group 2. In these patients, down-regulated genes included those related to immune response, NOD-like receptor signaling, RIG-I signaling, IL-17 signaling, and antioxidant activity. Conversely, up-regulated genes were found in the cGMP-PKG signaling pathway, cardiomyopathy-related pathways, and voltage-gated calcium channel activity. Conclusion: Patients receiving ICS with LABA plus omalizumab still exhibited more dynamic airway changes and higher IgE levels. Downregulation of immune and inflammatory pathways suggests its potential as an add-on treatment for severe asthma. However, upregulated genes were observed in the cGMP-PKG signaling pathway, cardiomyopathy-related pathways, and voltage-gated calcium channel activity.
- Open Access
- 27 May 2025
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 16 (2) , 200-209
Anti-inflammatory and polarization-modulating effects of Houttuynia cordata in LPS-stimulated RAW264.7 macrophages
- 27 May 2025
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 16 (2) , 200-209
Open AccessAnti-inflammatory and polarization-modulating effects of Houttuynia cordata in LPS-stimulated RAW264.7 macrophages
- Open Access
- 8 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 905
Interrelationship Between Obstructive Sleep Apnea Syndrome and Small Airway Disease: A Comprehensive Review
Study Objectives: This review aims to explore the epidemiology, pathophysiology, risk factors, and diagnostic approaches of obstructive sleep apnea syndrome and small airway disease, emphasizing their interrelationship and implications for clinical management. Methods: A comprehensive analysis of the literature was conducted to examine shared and distinct characteristics of obstructive sleep apnea syndrome and small airway disease. Risk factors, clinical presentations, diagnostic tools, and management strategies were reviewed to identify potential areas for improvement in care. Results: Obstructive sleep apnea syndrome, characterized by intermittent upper airway obstruction during sleep, contributes to fragmented sleep and systemic diseases. Small airway disease involves inflammation and obstruction of the small airways, impairing airflow and gas exchange. Shared risk factors, such as obesity, smoking, and age, were identified as contributors to the development and progression of both conditions. The co-occurrence of obstructive sleep apnea syndrome and small airway disease exacerbates respiratory symptoms and increases the risk of comorbidities, such as pulmonary hypertension, heart failure, and respiratory failure. Recognition of their interplay highlights the need for integrated diagnostic and therapeutic strategies. Conclusions: The interrelationship between obstructive sleep apnea syndrome and small airway disease underscores the importance of integrated management approaches to improve patient outcomes. Addressing shared risk factors and understanding the interplay between these conditions are crucial for optimizing care. This review identifies key knowledge gaps, including the need for precise diagnostic tools and targeted therapies, which are essential for advancing personalized treatment strategies for individuals with obstructive sleep apnea syndrome and small airway disease.
- 8 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 905
Open AccessInterrelationship Between Obstructive Sleep Apnea Syndrome and Small Airway Disease: A Comprehensive Review
Study Objectives: This review aims to explore the epidemiology, pathophysiology, risk factors, and diagnostic approaches of obstructive sleep apnea syndrome and small airway disease, emphasizing their interrelationship and implications for clinical management. Methods: A comprehensive analysis of the literature was conducted to examine shared and distinct characteristics of obstructive sleep apnea syndrome and small airway disease. Risk factors, clinical presentations, diagnostic tools, and management strategies were reviewed to identify potential areas for improvement in care. Results: Obstructive sleep apnea syndrome, characterized by intermittent upper airway obstruction during sleep, contributes to fragmented sleep and systemic diseases. Small airway disease involves inflammation and obstruction of the small airways, impairing airflow and gas exchange. Shared risk factors, such as obesity, smoking, and age, were identified as contributors to the development and progression of both conditions. The co-occurrence of obstructive sleep apnea syndrome and small airway disease exacerbates respiratory symptoms and increases the risk of comorbidities, such as pulmonary hypertension, heart failure, and respiratory failure. Recognition of their interplay highlights the need for integrated diagnostic and therapeutic strategies. Conclusions: The interrelationship between obstructive sleep apnea syndrome and small airway disease underscores the importance of integrated management approaches to improve patient outcomes. Addressing shared risk factors and understanding the interplay between these conditions are crucial for optimizing care. This review identifies key knowledge gaps, including the need for precise diagnostic tools and targeted therapies, which are essential for advancing personalized treatment strategies for individuals with obstructive sleep apnea syndrome and small airway disease.
- Open Access
- 3 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3365
Unraveling the Immune Landscape of Chronic Obstructive Pulmonary Disease: Insights into Inflammatory Cell Subtypes, Pathogenesis, and Treatment Strategies
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disorder characterized by persistent airway inflammation and progressive airflow limitation, resulting in a significant global health burden and high mortality. This narrative review synthesizes the current evidence on the roles of leukocyte subtypes—including neutrophils, monocytes, lymphocytes, eosinophils, and basophils—in the pathogenesis and clinical management of COPD. Relevant original studies and reviews are included, providing data on leukocyte functions, associated biomarkers, and therapeutic implications. Neutrophils contribute to airway damage and remodeling by releasing proteases and reactive oxygen species, particularly in response to environmental exposure such as cigarette smoke or air pollution. Lymphocytes, especially CD8⁺ T cells, drive chronic inflammation and immune dysregulation. Monocytes differentiate into macrophages that promote airway fibrosis and persistent inflammation, further impairing lung function. Eosinophils, though classically linked to asthma, are now recognized for their role in eosinophilic COPD, where they are associated with an increased exacerbation risk and corticosteroid responsiveness. Basophils, though less studied, may influence airway inflammation through interactions with eosinophils and cytokine release. Understanding these immune cell dynamics provides insights into the heterogeneity of COPD and highlights potential targets for precision therapy. Tailored interventions based on inflammatory phenotypes may improve clinical outcomes and advance personalized treatment strategies.
- 3 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3365
Open AccessUnraveling the Immune Landscape of Chronic Obstructive Pulmonary Disease: Insights into Inflammatory Cell Subtypes, Pathogenesis, and Treatment Strategies
Chronic obstructive pulmonary disease (COPD) is a prevalent respiratory disorder characterized by persistent airway inflammation and progressive airflow limitation, resulting in a significant global health burden and high mortality. This narrative review synthesizes the current evidence on the roles of leukocyte subtypes—including neutrophils, monocytes, lymphocytes, eosinophils, and basophils—in the pathogenesis and clinical management of COPD. Relevant original studies and reviews are included, providing data on leukocyte functions, associated biomarkers, and therapeutic implications. Neutrophils contribute to airway damage and remodeling by releasing proteases and reactive oxygen species, particularly in response to environmental exposure such as cigarette smoke or air pollution. Lymphocytes, especially CD8⁺ T cells, drive chronic inflammation and immune dysregulation. Monocytes differentiate into macrophages that promote airway fibrosis and persistent inflammation, further impairing lung function. Eosinophils, though classically linked to asthma, are now recognized for their role in eosinophilic COPD, where they are associated with an increased exacerbation risk and corticosteroid responsiveness. Basophils, though less studied, may influence airway inflammation through interactions with eosinophils and cytokine release. Understanding these immune cell dynamics provides insights into the heterogeneity of COPD and highlights potential targets for precision therapy. Tailored interventions based on inflammatory phenotypes may improve clinical outcomes and advance personalized treatment strategies.